Level A· Stronger Clinical EvidenceSystematic ReviewPubMedOpen access

Current status of nanofat in the management of knee osteoarthritis: A systematic review.

Jeyaraman N., Shrivastava S., Ravi VR., Nallakumarasamy A., Jeyaraman M.

Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in World J Orthop (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
World J Orthop (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
39850037
PMCID
PMC11752481
DOI
10.5312/wjo.v16.i1.99690
Citations
2

Abstract (original English)

Background Osteoarthritis (OA) is a prevalent joint disorder requiring innovative treatment approaches. Aim To evaluate the use of nanofat, a specialized form of adipose tissue-derived cells, in the treatment of OA, by examining its efficacy, safety profile, mechanisms of action, comparative effectiveness, and long-term outcomes. Methods A comprehensive review of preclinical studies, clinical trials, and in vitro investigations was conducted. The included studies provided insights into the potential role of nanofat in OA treatment, addressing its efficacy, safety profile, mechanisms of action, comparative effectiveness, and long-term outcomes. Results Clinical studies consistently reported the efficacy of nanofat in providing pain relief and functional improvement in patients with OA. Local adverse events were limited to the injection site, such as localized pain and inflammation, and resolved within a few days to weeks. Systemic adverse events were rare, and no significant long-term complications were observed. Mechanistically, nanofat was found to enhance chondrocyte proliferation, reduce inflammation, and promote angiogenesis, thereby contributing to its therapeutic effects. Conclusion Nanofat therapy holds promise as a therapeutic option for managing OA, providing pain relief, functional improvement, and potential tissue regeneration. The safety profile of nanofat treatment

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research